Bristol-Myers Squibb announced results from its Phase 3 study of ipilimumab for the treatment of previously-untreated patients with unresectable stage III or IV metastatic melanoma. The study compared ipilimumab in combination with dacarbazine compared with dacarbazine alone. Treatment with ipilimumab met the primary endpoint of improving overall survival in previously-untreated patients with metastatic melanoma.
Ipilimumab is a novel T-cell potentiator that specifically blocks the inhibitory signal of CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. Suppression of CTLA-4 can augment the immune system’s T-cell response in fighting disease.
For more information call (800) 321-1335 or visit www.bms.com.